PulmonxCorp Deferred Long Term Liab vs Short Term Debt Analysis
LUNG Stock | USD 9.00 0.05 0.55% |
PulmonxCorp financial indicator trend analysis is much more than just breaking down PulmonxCorp prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether PulmonxCorp is a good investment. Please check the relationship between PulmonxCorp Deferred Long Term Liab and its Short Term Debt accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in PulmonxCorp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in PulmonxCorp Stock please use our How to Invest in PulmonxCorp guide.
Deferred Long Term Liab vs Short Term Debt
Deferred Long Term Liab vs Short Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of PulmonxCorp Deferred Long Term Liab account and Short Term Debt. At this time, the significance of the direction appears to have pay attention.
The correlation between PulmonxCorp's Deferred Long Term Liab and Short Term Debt is -0.81. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of PulmonxCorp, assuming nothing else is changed. The correlation between historical values of PulmonxCorp's Deferred Long Term Liab and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of PulmonxCorp are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Deferred Long Term Liab i.e., PulmonxCorp's Deferred Long Term Liab and Short Term Debt go up and down completely randomly.
Correlation Coefficient | -0.81 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.Short Term Debt
Most indicators from PulmonxCorp's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into PulmonxCorp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in PulmonxCorp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in PulmonxCorp Stock please use our How to Invest in PulmonxCorp guide.The PulmonxCorp's current Selling General Administrative is estimated to increase to about 93.9 M, while Tax Provision is projected to decrease to roughly 339.7 K.
PulmonxCorp fundamental ratios Correlations
Click cells to compare fundamentals
PulmonxCorp Account Relationship Matchups
High Positive Relationship
High Negative Relationship
PulmonxCorp fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 53.5M | 263.7M | 235.2M | 193.7M | 179.0M | 94.4M | |
Total Current Liabilities | 14.2M | 12.5M | 17.6M | 18.5M | 23.2M | 24.3M | |
Total Stockholder Equity | (187.4M) | 226.1M | 193.2M | 154.0M | 118.3M | 124.2M | |
Net Tangible Assets | (190.2M) | 223.4M | 190.6M | 151.7M | 174.4M | 183.1M | |
Retained Earnings | (210.5M) | (242.7M) | (291.4M) | (350.3M) | (411.2M) | (390.6M) | |
Accounts Payable | 2.7M | 1.5M | 1.6M | 1.8M | 1.5M | 1.2M | |
Cash | 14.8M | 231.6M | 148.5M | 101.7M | 83.8M | 58.6M | |
Long Term Debt | 15.0M | 17.4M | 17.3M | 17.2M | 35.1M | 36.8M | |
Inventory | 5.6M | 10.7M | 16.3M | 14.6M | 16.7M | 17.6M | |
Total Liab | 240.9M | 37.6M | 41.9M | 39.7M | 60.6M | 61.5M | |
Total Current Assets | 41.1M | 250.0M | 208.0M | 169.0M | 150.3M | 83.2M | |
Short Term Debt | 446K | 2.2M | 2.3M | 3.3M | 5.2M | 5.5M | |
Common Stock | 19K | 36K | 37K | 38K | 39K | 25.0K | |
Property Plant Equipment | 7.5M | 10.5M | 12.9M | 5.3M | 6.1M | 4.1M | |
Net Receivables | 5.9M | 4.2M | 6.6M | 8.7M | 13.4M | 14.1M | |
Other Assets | 2.1M | 536K | 731K | 5.8M | 1.0 | 0.95 | |
Other Current Assets | 766K | 3.2M | 4.9M | 4.3M | 2.8M | 2.0M | |
Intangible Assets | 524K | 400K | 277K | 154K | 31K | 29.5K | |
Short Long Term Debt Total | 21.8M | 27.2M | 26.5M | 24.4M | 41.4M | 32.1M | |
Other Current Liab | 10.9M | 8.7M | 13.5M | 13.3M | 16.3M | 12.6M | |
Other Liab | 43K | 62K | 37K | 94K | 84.6K | 58.1K | |
Property Plant And Equipment Net | 7.5M | 10.5M | 12.9M | 10.5M | 7.4M | 9.0M | |
Current Deferred Revenue | 173K | 71K | 163K | 120K | 104K | 102.7K | |
Net Debt | 7.0M | (204.3M) | (122.0M) | (77.3M) | (42.4M) | (44.5M) | |
Non Current Assets Total | 12.5M | 13.7M | 27.2M | 24.7M | 28.6M | 20.2M | |
Non Currrent Assets Other | 2.1M | 536K | 252K | 5.4M | 3.3M | 2.2M | |
Cash And Short Term Investments | 28.3M | 231.6M | 180.0M | 141.1M | 117.3M | 128.8M | |
Common Stock Total Equity | 19K | 36K | 37K | 38K | 43.7K | 32.3K | |
Common Stock Shares Outstanding | 35.4M | 35.7M | 36.1M | 37.1M | 38.0M | 37.2M | |
Liabilities And Stockholders Equity | 53.5M | 263.7M | 235.2M | 193.7M | 179.0M | 172.3M | |
Non Current Liabilities Total | 226.8M | 25.0M | 24.4M | 21.2M | 37.5M | 67.9M | |
Capital Lease Obligations | 6.8M | 9.9M | 9.0M | 7.1M | 4.2M | 6.8M | |
Other Stockholder Equity | (183.6M) | 467.1M | 482.9M | 502.7M | 526.8M | 333.1M | |
Net Invested Capital | (172.4M) | 243.5M | 210.7M | 171.3M | 155.6M | 87.1M | |
Property Plant And Equipment Gross | 7.5M | 10.5M | 4.8M | 4.7M | 12.3M | 7.3M | |
Accumulated Other Comprehensive Income | 1.4M | 1.7M | 1.7M | 1.6M | 2.6M | 1.9M | |
Capital Stock | 19K | 36K | 37K | 38K | 39K | 34.1K | |
Net Working Capital | 26.9M | 237.5M | 190.5M | 150.5M | 127.3M | 134.9M |
Currently Active Assets on Macroaxis
When determining whether PulmonxCorp is a strong investment it is important to analyze PulmonxCorp's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact PulmonxCorp's future performance. For an informed investment choice regarding PulmonxCorp Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in PulmonxCorp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in PulmonxCorp Stock please use our How to Invest in PulmonxCorp guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Complementary Tools for PulmonxCorp Stock analysis
When running PulmonxCorp's price analysis, check to measure PulmonxCorp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PulmonxCorp is operating at the current time. Most of PulmonxCorp's value examination focuses on studying past and present price action to predict the probability of PulmonxCorp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PulmonxCorp's price. Additionally, you may evaluate how the addition of PulmonxCorp to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is PulmonxCorp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PulmonxCorp. If investors know PulmonxCorp will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PulmonxCorp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.54) | Revenue Per Share 1.909 | Quarterly Revenue Growth 0.297 | Return On Assets (0.21) | Return On Equity (0.46) |
The market value of PulmonxCorp is measured differently than its book value, which is the value of PulmonxCorp that is recorded on the company's balance sheet. Investors also form their own opinion of PulmonxCorp's value that differs from its market value or its book value, called intrinsic value, which is PulmonxCorp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PulmonxCorp's market value can be influenced by many factors that don't directly affect PulmonxCorp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PulmonxCorp's value and its price as these two are different measures arrived at by different means. Investors typically determine if PulmonxCorp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PulmonxCorp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.